Breaking News

Cook General Bio To Make HemaXellerate I

By Gil Roth | November 1, 2013

Regen BioPharma signs clinical supply contract

Bio-Matrix Scientific Group's Regen BioPharma subsidiary will use Cook General Biotechnology as its CMO to make clinical supplies of HemaXellerate I. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia. The initial batches will be utilized for completing preclinical experiments requested by the FDA for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia.

"We are excited to work with the team at Regen BioPharma in producing clinical grade HemaXellerate I, initially for preclinical studies, and subsequently for the clinical trial itself," said Erik J. Woods, Ph.D., chief executive officer of Cook General Biotechnology.

Related Compliance:

blog comments powered by Disqus
  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research